Background: ChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been licensed for emergency use for COVID-19. We assessed the safety and immunogenicity of the ChAdOx1 MERS vaccine in a phase 1b trial in healthy Middle Eastern adults.
Method: MERS002 is an open-label, non-randomised, dose-escalation, phase 1b trial.
Background: Cardiovascular diseases (CVD) are among the main causes of premature death and hospital admission worldwide, constituting a great economic burden on health care systems. Additionally, thyroid diseases may exert a deleterious effect on the outcomes of CVD patients.
Aim: This study was conducted to identify the pattern and factors associated with CVD distribution and the relation with thyroid dysfunction in the study population.